We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Aptamer Group Plc | APTA | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.415 | 07:34:52 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.415 |
| Industry Sector |
|---|
| HEALTH CARE EQUIPMENT & SERVICES |
| Top Posts |
|---|
Posted at 19/1/2025 21:24 by purchaseatthetop 19/12/24 RNS“Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, today announces the signing of a new development contract with a rare disease biopharmaceutical company. The agreement, worth up to £155,000,” So, this £155k might be worth £110k, might start April and maybe £55k earned in y.e 30/6/25. So that slightly increases the £400k to £600k gross margin by £27.5k. You need a lot more than that. |
Posted at 19/12/2024 07:46 by someuwin Shows the great business model here - near term cash generation via their bread and butter work with the potential for blue sky revenue from licensing."Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, today announces the signing of a new development contract with a rare disease biopharmaceutical company. The agreement, worth up to £155,000, focuses on developing two Optimer binders as critical reagents for therapeutic monitoring. Upon successful development, Aptamer could receive a significant undisclosed IP transfer fee for the use of the Optimers in clinical trial monitoring." |
Posted at 13/12/2024 08:31 by someuwin Alzheimer's Test.Two revenue streams - at home lateral flow test strips. and Clinical device. APTA Aptamers have been validated - They work and will detect Alzheimer's twenty years before symptoms appear! FDA awarded ROCHE the first and only early detection test this year but this requires blood test. APTA are closer than anyone to produce a simple saliva based early detection test. Alzheimer's test market will grow to 7bn per year. APTA could be a major early mover in this market. And that's just one of APTA's multiple pipelines. |
Posted at 06/11/2024 07:04 by affc21 Aptamer Group plc ("Aptamer", the "Company" or the "Group") Commercial Trading Update Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, is pleased to provide an update on contracts signed since its financial year ended 30 June 2024. Aptamer has secured new contracts worth up to £471,000 continuing the positive commercial traction achieved during the last quarter of the previous financial year. These contracts include multiple agreements, including two from top 20 and one from a top 5 global pharmaceutical companies, totalling up to £340,000. These projects are aimed at developing Optimers as critical reagents to support active clinical development programmes and facilitate the analysis of novel therapeutics. A significant proportion of these deals involve repeat customers who are advancing Aptamer's binders within their internal pipelines, with some signalling intent for long-term licensing revenues. This ongoing traction highlights Aptamer's role in supporting key industry players and reinforces our position as a key player in the market.These new contracts illustrate Aptamer's increasing commercial traction and the Group's ability to secure repeat business from top pharmaceutical companies. Aptamer now has booked revenue contracts of up to c. £1.2m to recognise throughout FY25 (Jun 25 year-end) and an increased sales pipeline from £2.1m in July 2024 to £4.0m as of today.Dr Arron Tolley, Chief Executive Officer of Aptamer Group said: "Following the fundraise in August 2024, I am pleased to report that the sustained focus of our commercial team continues to bear fruit. We are advancing steadily towards our revenue and potential licensing goals for FY 25 with the best part of 7 months left in the financial year. Revenue generation and increased income from licensing form a pivotal component of the Group's strategy to deliver shareholder value and I look forward to updating you on future contracts and key project updates."? - Ends -? |
Posted at 17/10/2024 09:33 by someuwin 17 October 2024Aptamer Group plc ("Aptamer", the "Company" or the "Group") Notice of Results and Investor Presentation Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, will announce its full year results for the year ended 30 June 2024 on Tuesday, 22 October 2024. The Company is pleased to announce that Dr Arron Tolley, Chief Executive Officer and Andrew Rapson, Chief Financial Officer will provide a live presentation relating to the full year results via Investor Meet Company on Tuesday, 22 October 2024 at 2:00 pm GMT. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet Aptamer Group plc via: hxxps://www.investor Investors who already follow Aptamer Group plc on the Investor Meet Company platform will automatically be invited. |
Posted at 03/9/2024 06:52 by timbo003 Today’s announcement adds a bit more meat to the bones regarding Unilever’s utilisation of aptamers for odour control.I suspect that Unilever were inspired to look at aptamers for odour control after picking up on P&Gs patent application ( WO2020214784A1 Aptamers for odour control applications) published in October 2020 The P&G/Neo-Ventures patent application proposes using aptamers that have a high binding affinity and specificity for malodorous molecules, whereas the Unilever/APTA work concerns targeting the C-S Lyase bacterial enzyme, which is critical in the generation of the malodrous molecules. Intuitively the Unilever approach seems more logical (and hopefully more effective) as it is intended to intervene earlier in the pathway of malodour generation. Furthermore, it is a completely different approach to that employed by P&G thus avoiding any infringement of P&G intellectual property (should P&G’s patent be granted). |
Posted at 03/7/2024 06:34 by gepetto100 Aptamer Group plc("Aptamer", the "Company" or the "Group")Agreement to explore Optimer vehicles for targeted delivery of siRNA- New collaboration will evaluate Aptamer's fibrotic liver delivery vehicles with siRNA Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, is pleased to announce a new agreement with AstraZeneca, a global biopharmaceutical company, to evaluate the Optimer fibrotic liver delivery vehicles for the targeted delivery of siRNA. Following the encouraging results achieved to-date with Aptamer's fibrotic liver delivery vehicles, the next phase of this research will explore the potential of the non-viral delivery vehicle and its applicability with a tool siRNA. Under the agreement, AstraZeneca will provide an siRNA to be trialled with Aptamer's Optimer-based delivery vehicle for fibrotic liver cells. Aptamer Group will conduct in-house experimental work to assess the effectiveness of this delivery vehicle with the AstraZeneca's siRNA. Upon success, Aptamer Group will progress to internally generating demonstrator data in animal models for evaluation by AstraZeneca. Delivery of siRNA to precise cell types and tissues with successful cell internalisation remains a significant challenge for the wider therapeutic application of the technology. Despite this limitation, the siRNA market was still valued at over $13 billion in 2023. Optimer technology could represent a paradigm shift in the targeted delivery of siRNA molecules, due to the high levels of selectivity, high affinity and simple conjugation of siRNA payloads, offered using Optimer delivery systems as non-viral vectors. If successful Optimer-enabled delivery of siRNA could lead to the development of novel compounds that have significant advantages over current cell and tissue-targeting methods. Dr Arron Tolley, Chief Technical Officer of Aptamer Group, said: "We are really excited to work with AstraZeneca to evaluate and optimise our Optimer delivery vehicles."Partnershi |
Posted at 24/6/2024 06:12 by multibagger Good morning all :)Another excellent RNS and further proof that a number of contracts being signed and many more to come ! RNS Number : 4897T Aptamer Group PLC 24 June 2024 Aptamer Group Announces New Contracts Worth £235,000 for Optimer Development - Contract with top five pharma partner for IHC reagents - Contract to develop Optimer for life science kits with royalty-bearing licence upon commercialisation Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, is pleased to announce the signing of two significant contracts for the development of Optimer binders, with a combined total value of up to £235,000. The first contract, valued at up to £175,000, is with a top five pharmaceutical company. As part of this contract, Aptamer will develop Optimer binders for use in immunohistochemistry (IHC) applications. There is potential for the Optimer binders to utilise the Company's recently patented Optimer-Fc platform to deliver advanced IHC reagents for improved performance and use in automated IHC workflows. Following development, the binders could be integrated into companion diagnostics or as critical reagents to support the top five partner's drug development pipeline, resulting in downstream royalties and/or licencing revenues for Aptamer. This agreement represents the sixth contract with this pharmaceutical partner for Optimer development across multiple applications, highlighting its confidence in the Optimer platform. The second contract, valued at up to £60,000, is with a global provider of specialty enzymes used widely throughout the life sciences sector, in a $9.9bn market, growing at 8.6% CAGR. Aptamer will develop Optimer binders as novel reagents to be incorporated into the partner's life science and diagnostic assay kits. Through a non-exclusive licence for the developed Optimer, Aptamer Group will earn milestone payments upon successful commercialisation and downstream high single digit royalties from the gross sales of all kits containing the developed Optimer. Sales could commence as early as 2025. Dr Arron Tolley, Chief Technical Officer of Aptamer Group, said: "The repeat business from another of our top-five pharma partner validates the power of the Optimer platform to solve intractable problems associated with traditional ligands like antibodies in the area of immunohistochemistry (IHC) and supports our new business and patenting strategy. These smaller royalty bearing agreements to develop Optimer binders aligns with our business model to develop a diversified pipeline of technologies to deliver licence agreements across the life science sector. Unfortunately, due to confidentiality we cannot disclose the name of the partner or any other terms of the deal. Over the past year, the new management team has successfully rebuilt the sales pipeline, and refocused the business to its pre-IPO model which continues to convert to signed deals - with opportunities to generate passive income through licensing and royalty-based deals. I look forward to updating the market on continuing commercial progress and on the continued development of our key assets in delivery vehicles for the Liver Fibrosis, binders for cosmetic applications with Unilever and our ongoing partnership with Neuro-Bio developing a diagnostic for Alzheimer's." - ENDS - |
Posted at 22/5/2024 07:53 by citys2874 RNSAptamer Group plc ("Aptamer", the "Company" or the "Group") Aptamer and Timser partner to deliver world's first blood test for cervical cancer Agreement for up to £465,000 signed for Optimer development Optimer binders will be developed for use in a cervical cancer blood test Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, has signed an agreement with Timser Group, a pharmaceutical company focused on women's health, with a deal value of up to £465,000. Under the terms of the agreement, Aptamer Group will develop Optimer binders to Timser's patented cervical cancer biomarker panel - a three-protein signature that can be used to detect cervical cancer and precancerous lesions. The Optimers will power the world's first blood test for cervical cancer, preventing invasive smear tests and delivering earlier, more sensitive diagnostics. Pairs of Optimer binders will be developed to each of the three biomarker proteins that form the unique cervical cancer signature. Timser will receive a licence for the use of the Optimers in its specific test combination, which is patented in 21 countries, including the USA. Cervical cancer is the fourth most common cancer type in women worldwide. Present screening methods rely on invasive and relatively low sensitivity Papanicolaou (PAP) smear tests. The Optimer enabled Timser's diagnostic will allow earlier detection at the precancerous lesion stage, which is associated with increased survival. Use of a blood-based test over traditional PAP smears will offer the potential for increased detection rates by improving uptake due to the less invasive testing method. As Timser expands its diagnostic tests into diverse markets, including low-income countries, the Optimer binders offer advantages to support continued supply and quality. With superior shelf-life and enhanced temperature stability compared to antibodies, Optimer binders facilitate global test distribution without compromising quality or performance. Previous attempts by Timser to develop antibodies to support the test have failed due to issues with antibody batch variability and supply chains. Unlike antibodies, Optimer binders are chemically manufactured, giving consistent quality, with the potential to use multiple manufacturers both locally and globally to prevent supply chain issues. Dr Arron Tolley, Chief Technical Officer of Aptamer Group, said: "We are delighted to partner with Timser Group to facilitate their ground-breaking cancer diagnostic with Optimer binders. This deal demonstrates the increasing recognition of the Optimer platform to deliver high quality affinity ligands. We believe that implementing Optimer technology will allow our partners to overcome previous issues experienced with antibody variability and supply chains, and we look forward to delivering much-needed improvements to cervical cancer tests." Mercedes Gutierrez, Chief Executive Officer of TIMSER Group: "We are equally excited about this collaboration with Aptamer Group. The potential of Optimer binders to enhance the accuracy and reliability of our cancer diagnostics tests is truly promising. By integrating this advanced technology, we are confident in our ability to overcome the limitations of traditional antibodies and improve the outcomes for patients undergoing cervical cancer screening. We look forward to a successful partnership and to witnessing the impact that this new technology will have for women across the globe." |
Posted at 13/5/2024 07:10 by multibagger Good morning all !A welcome trading update and sales pipeline has increased further to £3.0m ! "....Additionally, there is considerable potential for significant value delivery from ongoing activities in the drug delivery space, with a growing interest from various companies seeking to address the substantial unmet need in this field using Optimer and Optimer+ technologies.... Emphasis in bold mine :) RNS Number : 1321O Aptamer Group PLC 13 May 2024 Aptamer Group plc ("Aptamer", the "Company" or the "Group") Trading update Aptamer Group plc (AIM: APTA ), the developer of novel Optimer® binders to enable innovation in the life sciences industry, today announces a trading update. Following fundraising in August 2023, Aptamer set out three strategic objectives: (1) to achieve EBITDA and cash break-even position within two years, (2) to implement platform process improvements, and (3) to generate marketing data and increase commercial traction by broadening the service offering to the market. Aptamer remains firmly focussed on the first of these three objectives and is pleased to report progress on the second two objectives. Since the announcement of the half year results, the Group has made significant progress in regarding its new platform technology, Optimer®+, through an initial soft launch and agreement of the first commercial sale. Patents have been filed to protect the Optimer binders developed in partnership with Unilever for use in cosmetics applications to support ongoing commercial discussions between the two companies, with further testing underway. A follow-on deal has been signed with Neuro-Bio to develop a second Optimer binder to enable a wholly Optimer-powered lateral flow test for the early detection of Alzheimer's disease. Furthermore, the Group has made significant progress in the precision gene therapy space, demonstrating Optimer performance in lab-based tests as drug delivery vehicles specific to the cells associated with fibrotic liver disease and establishing chemical manufacturing methods for scaled test batches. These Optimer-conjugates are currently undergoing evaluation by a top 15 pharma partner, with additional negotiations underway with a major top 10 pharmaceutical company to explore the Optimer-conjugates as part of a proof-of-concept study. The Group's current sales pipeline is strong, with over £3.0 million in advanced stage discussions. A proportion of these advanced stage deal negotiations is anticipated to progress through the laboratory before the end of the financial year. This anticipated deal value is in addition to the c.£1.4m of existing signed deals already at various stages of completion in the production laboratory. Revenue recognition on all signed deals is further subject to the receipt of target material in a timely manner from customers, and scientific attrition. The Company continues to make strides in rebuilding the sales pipeline and revitalizing operations throughout the laboratory, leading to a growing pipeline conversion, including the successful acquisition of repeat business. The Company looks forward to providing further updates on conversion of the pipeline to contracts before the year end. Additionally, there is considerable potential for significant value delivery from ongoing activities in the drug delivery space, with a growing interest from various companies seeking to address the substantial unmet need in this field using Optimer and Optimer+ technologies. - ENDS - |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
